Arcturus therapeutics announces third quarter 2022 financial update and pipeline progress

San diego--(business wire)--arcturus therapeutics holdings inc. (the “company”, “arcturus”, “arcturus therapeutics”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended september 30, 2022, and provided corporate updates.
ARCT Ratings Summary
ARCT Quant Ranking